What are analysts saying about ResMed, Downer, and Nuix shares?

MotleyFool03-16 11:30

Analysts have been busy running the rule over a number of popular ASX shares. But what are they saying about them? Let's find out if analysts are bullish or bearish, courtesy of The Bull. Here's what ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619143369?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 11:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619143369","market":"nz","top_or_hot":-1,"title":"What are analysts saying about ResMed, Downer, and Nuix shares?","media":"MotleyFool","content":"<div>\n<p>Analysts have been busy running the rule over a number of popular ASX shares.\nBut what are they saying about them? Let's find out if analysts are bullish or bearish, courtesy of The Bull. Here's what ...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/16/what-are-analysts-saying-about-resmed-downer-and-nuix-shares/\">Source Link</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What are analysts saying about ResMed, Downer, and Nuix shares?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat are analysts saying about ResMed, Downer, and Nuix shares?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-16 11:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com.au/2026/03/16/what-are-analysts-saying-about-resmed-downer-and-nuix-shares/><strong>MotleyFool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Analysts have been busy running the rule over a number of popular ASX shares.\nBut what are they saying about them? Let's find out if analysts are bullish or bearish, courtesy of The Bull. Here's what ...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/16/what-are-analysts-saying-about-resmed-downer-and-nuix-shares/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4504","symbol_name":"桥水持仓","start_time":0,"source_url":"https://www.fool.com.au/2026/03/16/what-are-analysts-saying-about-resmed-downer-and-nuix-shares/","article_id":"2619143369","we_media_id":null,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/16/what-are-analysts-saying-about-resmed-downer-and-nuix-shares/","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619143369","pubTimestamp":1773631800,"columns":[],"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"Analysts have been busy running the rule over a number of popular ASX shares.Let's find out if analysts are bullish or bearish, courtesy of The Bull. Here's what you need to know:. Baker Young reckons that investors should be selling this integrated services provider's shares this week.The broker highlights that its current valuation leaves little margin for error and poses meaningful downside risk should trading conditions soften. It said:. Downer provides integrated services that maintains infrastructure across Australia and New Zealand. It's benefited from highly supportive macroeconomic conditions and favourable government infrastructure spending during the past two years. The company's first half result in fiscal year 2026 highlighted statutory net profit after tax of $98 million, up 29.8 per cent on the prior corresponding period.Management expects further margin expansion through fiscal years 2026 and 2027. However, the share price increase has far outpaced underlying earnings g","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4504":"桥水持仓","BK4548":"巴美列捷福持仓","BK7501":"新冠治疗股","RMD.AU":"Resmed DRC","RMD":"瑞思迈","LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","BK7016":"应用软件","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","BK4588":"碎股","BK7007":"医疗保健设备","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","NXL.AU":"NUIX LTD","BK7064":"综合支持服务","BK4082":"医疗保健设备","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","DOW.AU":"DOWNER EDI LTD"},"translate_title":"分析师对ResMed、Downer和Nuix股票有何评价？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD.AU":1,"RMD":1.5,"NXL.AU":1,"DOW.AU":1},"content_text":"Analysts have been busy running the rule over a number of popular ASX shares.\nBut what are they saying about them? Let's find out if analysts are bullish or bearish, courtesy of The Bull. Here's what you need to know:\nImage source: Getty Images\nDowner EDI Ltd (ASX: DOW)\nBaker Young reckons that investors should be selling this integrated services provider's shares this week.\nThe broker highlights that its current valuation leaves little margin for error and poses meaningful downside risk should trading conditions soften. It said:\nDowner provides integrated services that maintains infrastructure across Australia and New Zealand. It's benefited from highly supportive macroeconomic conditions and favourable government infrastructure spending during the past two years. The company's first half result in fiscal year 2026 highlighted statutory net profit after tax of $98 million, up 29.8 per cent on the prior corresponding period.\nManagement expects further margin expansion through fiscal years 2026 and 2027. However, the share price increase has far outpaced underlying earnings growth. At current valuation levels, we see limited margin for error and little valuation support should conditions soften. Consequently, we believe it's prudent to take profits.\nNuix Ltd (ASX: NXL)\nAnother ASX share that has been named as a sell is investigative and analytics software provider Nuix.\nPeak Asset Management thinks that its shares are fully valued now and that investors should be taking profit. Talking about the tech stock, it said:\nNuix is an investigative analytics software provider. It enables customers to process and search large data sets of unstructured information, including emails, documents and communications records. The company earns most of its revenue from licence and maintenance fees. Revenue of $121.2 million in the first half of fiscal year 2026 was up 15.2 per cent on the prior corresponding period.\nAnnualised contract value of $234.4 million was up 8.4 per cent. Investors may want to consider taking a profit as we believe gains are priced in following the half year result. We see limited scope for upside amid increasing competition.\nResMed Inc. (ASX: RMD)\nOver at Securities Vault, its analysts think this sleep disorder treatment company's shares are a hold.\nIt is a big fan of ResMed but feels its shares are fully valued at current levels and recommends waiting for a better entry point. It said:\nResMed remains a global leader in sleep apnoea devices and digital health monitoring. Structural demand drivers, including ageing populations, increasing diagnosis rates and broader awareness of sleep health, continue to support long term growth. However, a strong share price recovery following concerns about the impact of weight loss drugs on sleep apnoea treatment appears to leave much of the near-term optimism priced into the stock.\nWhile the company's fundamentals remain robust, the valuation reflects its market leadership and growth outlook. Investors may prefer to retain existing positions, while awaiting further earnings expansion, or more attractive entry points.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619143369","isCrawlerRequest":true}